Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 5/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23046025 | 1.00 | GPR119 (0.39) | GPR119TSHRALOX15NAMPTRORC | |
| SCHEMBL29760948 | 1.00 | GPR119 (0.39) | GPR119TSHRALOX15NAMPTRORC | |
| SCHEMBL31317540 | 1.00 | GPR119 (0.39) | GPR119TSHRALOX15NAMPTRORC | |
| SCHEMBL30486574 | 1.00 | GPR119 (0.39) | GPR119TSHRALOX15NAMPTRORC | |
| SCHEMBL26317279 | 1.00 | GPR119 (0.39) | GPR119TSHRALOX15NAMPTRORC | |
| SCHEMBL24635800 | 1.00 | GPR119 (0.39) | GPR119TSHRALOX15NAMPTRORC | |
| SCHEMBL31492738 | 1.00 | GPR119 (0.39) | GPR119TSHRALOX15NAMPTRORC | |
| SCHEMBL29832328 | 0.90 | TSHR (0.38) | GPR119TSHRALOX15NAMPTATM | |
| SCHEMBL21940374 | 0.90 | TSHR (0.38) | GPR119TSHRALOX15NAMPTATM | |
| SCHEMBL21941112 | 0.90 | TSHR (0.38) | GPR119TSHRALOX15NAMPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRODINGER, INC. | 2022-10-06 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | GPR119 1069/4885TSHR 3144/4885ALOX15 2800/4885 |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | GPR119 1069/4885TSHR 3144/4885ALOX15 2800/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | GPR119 1069/4885TSHR 3144/4885ALOX15 2800/4885 |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | GPR119 1659/4885TSHR 2929/4885ALOX15 3542/4885 |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | GPR119 1069/4885TSHR 3144/4885ALOX15 2800/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | GPR119 1069/4885TSHR 3144/4885ALOX15 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.